This model, in particular, relies on a 5-DRG signature of genes (ERO1A, KRT18, GALNT2, PPIA, and CAPN12), and we have explored these genes’ roles in LUAD, considering their impact on the tumor’s immune microenvironment, clinical characteristics, prognosis, and therapy approaches. This evidence concerns the gene CAPN12 and neoplasm.